The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index; 39 of the 112 sources its claims cite were checked for support.
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Open accessAbstract
Drug resistance is perhaps the greatest challenge in improving outcomes for cancer patients undergoing treatment with targeted therapies. It is becoming clear that “persisters,” a subpopulation of drug-tolerant cells found in cancer populations, play a critical role in the development of drug resistance. Persisters are able to maintain viability under therapy but are typically slow cycling or dormant. These cells do not harbor classic drug resistance driver alterations, and their partial resistance phenotype is transient and reversible upon removal of the drug. In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy. Thus, eliminating persister cells will be crucial to improve outcomes for cancer patients. Using lung cancer targeted therapies as a primary paradigm, this review will give an overview of the characteristics of drug-tolerant persister cells, mechanisms associated with drug tolerance, and potential therapeutic opportunities to target this persister cell population in tumors.
Overview
CoChat Summary
TL;DR
This review argues that drug-tolerant persister cells survive targeted therapy without bona fide resistance mutations, are often slow-cycling/dormant, and can serve as a reservoir from which acquired resistance evolves. It summarizes mechanisms of tolerance and potential therapeutic vulnerabilities, using lung cancer targeted therapies as the primary paradigm.
Key findings
- In the founding cancer persister study, ~0.3% of PC9 EGFR-mutant NSCLC cells survived lethal-dose erlotinib as slowly cycling drug-tolerant persisters; upon drug removal, expanded persisters reverted to a drug-sensitive state.
- Acquired resistance can evolve from persisters: in PC9 pools treated with gefitinib, 5–10% developed rapid EGFR T790M resistance as early as 2 weeks, while most underwent initial response followed by slow expansion of drug-tolerant cells and later full resistance.
- Clinical resistance mechanisms include secondary mutations such as EGFR T790M, bypass signaling such as MET activation in 5–10% of EGFR TKI-resistant lung cancers, and lineage transformation in 5–15% of EGFR-mutant lung cancer patients with acquired resistance.
- Persister mechanisms reviewed include epigenetic/chromatin reprogramming, bypass/alternative signaling, apoptosis suppression, metabolic reprogramming, tumor microenvironment interactions, and adaptive mutagenesis; clinical minimal residual disease is the closest analogue.
Methods
- Narrative review of in vitro, in vivo, and clinical studies on drug-tolerant persister cells, focused on targeted therapies for solid malignancies and using lung cancer as the primary paradigm.
- Synthesizes mechanistic studies and includes Table 1 cataloging tumor type, target oncogene, targeted therapy, model system, mechanism of drug tolerance, and susceptibility for each study.
- No systematic review, meta-analysis, or primary experimental methods are reported.
Limitations
- The paper states that understanding clinical persisters is limited by difficulty accessing tumor tissue at minimal residual disease, that molecular signatures indicating whether relapsed tumors passed through a persister state are undefined, and that the true extent of relapse from persister evolution versus pre-existing resistant clones remains unknown.
- The paper states that tumor microenvironment contributions cannot be addressed well by in vitro models or in vivo studies using immunocompromised mice, and that future work should prioritize on-treatment biopsies.
- Evident from the text: this is a narrative review without systematic search or quantitative synthesis, so conclusions depend on the selected literature and model systems discussed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
21 Valid · 0 Not valid · 88 Not checked · 30 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The results revealed a large fraction of shared barcodes within the cells treated with EGFR inhibitor alone, consistent with selection of pre-existing persister clones.”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 2. Origins and Characteristics of Persisters > 2.3. Origin of Drug-Tolerant Persister Cells
What the sources say
- Supportedcites [56] Kurppa, 2020, Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway, Cancer Cell source
The Results section (“Combined EGFR and MEK inhibition results in a stable, but reversible dormant state”; page not supplied) reports DNA barcoding of PC-9 cells and a large fraction of shared barcodes after gefitinib or osimertinib alone. The authors interpret this as strong evidence for selection of pre-existing clones. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Alternatively, cells may survive initial drug treatment by epigenetic adaptations that enable a drug-tolerant, slow-cycling phenotype that precedes the emergence of permanent drug resistance [23,24].”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 1. Introduction
What the sources say
- Supportedcites [23] Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell source
The Abstract and Introduction of Sharma et al. (2010) describe a reversibly drug-tolerant subpopulation maintained via an altered chromatin state requiring RBP2/KDM5A, i.e. an epigenetic adaptation, and the Results (p. 'Detection of a drug-tolerant cancer cell subpopulation') characterize the DTPs as 'largely quiescent' slow-cycling cells surviving an otherwise lethal exposure. The DISCUSSION states explicitly that such a transient drug-tolerant state lets a small subpopulation withstand the initial drug onslaught 'until more permanent resistance mechanisms can be established,' matching the claim's ordering of tolerance preceding permanent resistance. The claim's hedged wording ('may') is consistent with the source's own framing. (LLM, conf=0.93)
- Not checked yetcites [24] Guler, 2017, Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure, Cancer Cell source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Meanwhile, other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment [56,64,65].”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 2. Origins and Characteristics of Persisters > 2.3. Origin of Drug-Tolerant Persister Cells
What the sources say
- Supportedcites [56] Kurppa, 2020, Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway, Cancer Cell source
The Results section reports that entry into dormancy after EGFR/MEK inhibitor treatment was predominantly stochastic rather than selection of a pre-existing resistant clone. The Discussion describes cells reversibly adopting a dormant, senescent-like state during treatment and returning to their prior state after drug withdrawal. Together, these passages support the claim that some persister phenotypes arise through treatment-induced plasticity. Page numbers are unavailable in our copy. (LLM, conf=0.92)
- Supportedcites [64] Goldman, 2015, Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition, Nat. Commun. source
In Results, ‘Drug-induced phenotypic plasticity and tolerance’ (page not provided), the paper identifies drug-tolerant cells as persisters and reports that low-dose chemotherapy induced a CD44HiCD24Hi phenotype without selecting for surviving cells. It concludes that chemotherapy tolerance could arise from a drug-induced cell-state transition, matching the claim’s cautious wording. (LLM, conf=0.93)
- Partly supportedcites [65] Glasspool, 2006, Epigenetics as a mechanism driving polygenic clinical drug resistance, Br. J. Cancer sourceExperimental — accuracy not yet measured
The ‘Genetic vs Epigenetic Alterations of Resistance Genes’ section suggests that epigenetic changes allow tumour cells to adapt to cytotoxic drug therapy and produce persistent acquired resistance. It does not identify these cells as persisters or establish that persister phenotypes arise through treatment-induced plasticity. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Over time, a fraction of DTPs reinitiated proliferation in the presence of erlotinib, giving rise to a second population of cells labeled drug-tolerant expanded persisters (DTEPs).”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 2. Origins and Characteristics of Persisters > 2.2. Persisters in Cancer
What the sources say
- Supportedcites [23] Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell source
The Results section 'Detection of a drug-tolerant cancer cell subpopulation' (p. 1 of our copy) states that although DTPs are largely quiescent, approximately 20% eventually resume normal proliferation in the presence of drug, yielding colonies termed 'drug-tolerant expanded persisters' (DTEPs), which can be propagated indefinitely in drug. The 'Generation of DTEPs' procedures (Experimental Procedures) corroborate that clones of drug-resistant cells appear after ~30 days of continued erlotinib/gefitinib selection. Both the fraction ('a fraction') and the continued-drug condition in the citing sentence match the source. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Some studies indicate that drug-tolerant persister populations or cancer cells that are primed to persist exist even prior to treatment [40,43,60,61].”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 2. Origins and Characteristics of Persisters > 2.3. Origin of Drug-Tolerant Persister Cells
What the sources say
- Supportedcites [40] Hangauer, 2017, Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition, Nature source
The passage on RSL3 pretreatment (labeled Abstract in our copy; page not provided) says that reducing the later persister-cell pool is consistent with reports that persister cells may preexist drug treatment. This supports the citing sentence’s qualified claim that some studies indicate pretreatment existence. (LLM, conf=0.93)
- Supportedcites [43] Raha, 2014, The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation, Cancer Res. source
In “Drug-tolerant cancer cells express the CSC marker ALDH1A1,” the paper identifies ALDH-high cells before treatment and reports that they showed greater crizotinib tolerance than ALDH-low cells. The Discussion explicitly describes a preexisting subpopulation with characteristics of drug-tolerant cells. This supports the citing sentence’s qualified claim that some cancer cells are primed to persist before treatment. (LLM, conf=0.93)
- Supportedcites [60] Roesch, 2013, Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells, Cancer Cell source
In Results (“Dynamics of the therapy-resistant JARID1Bhigh phenotype”; page unavailable), the authors conclude that treatment mainly selects pre-existing slow-cycling JARID1Bhigh melanoma cells. This supports the claim that cells primed to survive treatment can exist beforehand, while the paper also allows that some cells may acquire the phenotype. (LLM, conf=0.93)
- Supportedcites [61] Shaffer, 2017, Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance, Nature source
The Abstract says that transcriptional variability in melanoma cells before treatment predicts which cells will resist the drug. It describes rare cells in a transient pre-resistant state that become stably resistant after drug-induced reprogramming, supporting the claim's 'primed to persist' alternative. (LLM, conf=0.92)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 13 with their cited sources checked
Create a free account to see all 139 claims and to verify the 73 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“in BRAF-mutated CRC, the response to single-agent BRAF inhibition is limited by EGFR-mediated adaptive feedback reactivation of MAPK signaling [237].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [237]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 3. Drug-Tolerant Persister Cells: Mechanisms of Drug Tolerance and Therapeutic Vulnerabilities > 3.1. Epigenetic Reprogramming/Plasticity
“| Melanoma | BRAF | Vemurafenib | SK-MEL-5, SK-MEL-28, G-361 | Stromal cell secretion of HGF | MAPK (PD184352), PI3K–AKT (crizotinib, MK-2206) | [99] |”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 3. Drug-Tolerant Persister Cells: Mechanisms of Drug Tolerance and Therapeutic Vulnerabilities > 3.5. Interactions with the Tumor Microenvironment
“Using either an HGF-blocking antibody or the MET small molecule inhibitor crizotinib to target the HGF–MET axis suppressed fibroblast-mediated resistance.”
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 2×
“Drug resistance to targeted therapies in cancer can be classified as primary or acquired (Figure 1A) [8,9].”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 4×
“For example, the discovery of MET amplification in a subset of resistant EGFR-mutant lung cancers [14] has now led to promising activity of combination EGFR and MET TKIs [103] in EGFR-mutant lung cancer patients with acquired resistance due to MET amplification.”
BackgroundInfluentialEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · cited 1×
“For example, in EGFR-mutant lung cancers, the point mutation leading to a substitution of methionine for threonine at amino acid position 790 in exon 20 of EGFR, known as the EGFR T790M gatekeeper mutation, is a leading cause of resistance to first- and second-generation EGFR inhibitors [11,12].”
BackgroundGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Bacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952 · cited 1×
“More recently, live imaging experiments have confirmed that these bacterial cells that survived antibiotic treatment were indeed not proliferating before the addition of antibiotics [30].”
Background
Cited by
Senescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
Meier, P., Legrand, A. J., Adam, D., & Silke, J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00674-x · Cited by 382
“Moreover, non-mutational drug resistance mechanisms can also support the survival of residual cancer persister cells , which then serve as a reservoir from which tumours can re-emerge 5,6 .”
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Yang, Y., Li, S., To, K. K. W., Zhu, S., Wang, F., & Fu, L. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03377-9 · Cited by 184
“A multifaceted array of factors, including driver oncogene mutations, epigenetic alterations, disruptions in critical signaling pathways, defects in the antigen-presenting pathway and immune evasion, are known to contribute to diminished effectiveness of immunotherapy [10–12].”
Metadata
- Authors
- Cabanos, H. F., & Hata, A. N.
- Affiliations
- Harvard University (US)
- Corresponding author
- Hata, Aaron N.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-05-28
- Volume
- 13
- Issue
- 11
- Pages
- 2666
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8198243
- OpenAlex
- W3164747206
- Semantic Scholar
- 2c8bf4ee4ae8fc459542c3b2c653293e06b91077
- Cited by
- 189
- References
- 131
- Citations by year
- 2026: 24 · 2025: 37 · 2024: 58 · 2023: 43 · 2022: 25 · 2021: 2
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (K08 CA197389, R01 CA137008)
- Doris Duke Charitable Foundation (Clinical Scientist Development Award)
- Stand Up To Cancer (Convergence 1.0 Team Award)
- V Foundation (Scholar Award)
- Ludwig Center at Harvard (N/A)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- drug-tolerant persister cells, targeted therapy, drug resistance, minimal residual disease, lung cancer, tumor dormancy, tumor recurrence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. https://app.cochat.ai/papers/10.3390/cancers13112666
- The paper
- Cabanos, H. F., & Hata, A. N. (2021). Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers. https://doi.org/10.3390/cancers13112666
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.